Muhammad Awwad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammad Awwad has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Amos Stemmer
Cancer Data Science Laboratory (CDSL), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA; Gray School of Medicine, Tel Aviv University, Tel Aviv, Israel
2 shared publications Asaf Ness
Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
1 shared publication- Asaf Ness
Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva 4941492, Israel
1 shared publication - Erez Bar-Haim
Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel
1 shared publication - Hila Cohen
Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel
1 shared publication Nassem Ghantous
Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
1 shared publication
Latest Publications
- Open Access
- 21 July 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (7) , e2223090
Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
At the beginning of the fifth SARS-CoV-2 wave in Israel, with the B.1.1.529 (Omicron) variant, the effectiveness of the third SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech) against Omicron was questioned. During the fifth wave, in January 2022, the Israeli Ministry of Health authorized a fourth BNT162b2 dose for individuals aged 60 years or older (a third dose was authorized for such individuals in July 2021, during the fourth SARS-CoV-2 wave).
- 21 July 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (7) , e2223090
Open AccessAntibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
At the beginning of the fifth SARS-CoV-2 wave in Israel, with the B.1.1.529 (Omicron) variant, the effectiveness of the third SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech) against Omicron was questioned. During the fifth wave, in January 2022, the Israeli Ministry of Health authorized a fourth BNT162b2 dose for individuals aged 60 years or older (a third dose was authorized for such individuals in July 2021, during the fourth SARS-CoV-2 wave).
- Open Access
- 8 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2649
Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
Both humoral and cellular anamnestic responses are significant for protective immunity against SARS-CoV-2. In the current study, the responses in elderly people before and after a fourth vaccine dose of BNT162b2 were compared to those of individuals immunized with three vaccine doses. Although a boost effect was observed, the high response following the third administration questions the necessity of an early fourth boost.
- 8 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (9) , 2649
Open AccessHumoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
Both humoral and cellular anamnestic responses are significant for protective immunity against SARS-CoV-2. In the current study, the responses in elderly people before and after a fourth vaccine dose of BNT162b2 were compared to those of individuals immunized with three vaccine doses. Although a boost effect was observed, the high response following the third administration questions the necessity of an early fourth boost.